Proteome Sciences PLC Publication: Journal of Alzheimer's disease
22 September 2016 - 4:01PM
RNS Non-Regulatory
TIDMPRM
Proteome Sciences PLC
22 September 2016
PRESS RELEASE
Proteome Sciences plc
Study Demonstrates Mass Spectrometry Technique Dramatically
Enhances Detection of Key Early Stage Alzheimer's Biomarkers.
Publication: Journal of Alzheimer's disease
For immediate release: 22nd September 2016, Cobham, UK: A peer
reviewed study led by Proteome Sciences plc ("Proteome Sciences"),
in conjunction with a group of highly respected universities and
hospitals, demonstrates the ability of an innovative mass
spectrometry (MS) workflow to dramatically improve the ability to
detect tau-derived peptides that are directly related to human
Alzheimer's pathology as early stage biomarkers of the disease.
Published on-line in the Journal of Alzheimer's Disease , the
study describes the application of the workflow, TMTcalibrator, for
high-sensitivity detection of phosphorylated tau and other
disease-relevant biomarkers of Alzheimer's disease (AD) in
cerebrospinal fluid (CSF).
The TMTcalibrator workflow combines analysis of diseased tissue
and body fluids to enhance mass spectrometric detection of
tissue-derived biomarkers at unparalleled levels of
sensitivity.
Demonstrating this, the study, the first to be published using
TMTcalibrator, reports the detection of 47 tau phosphopeptides
covering 31 clinically-relevant phosphorylation sites. In total
76.8% coverage of human tau in CSF was obtained.
Previous attempts to profile phosphorylated tau in CSF using
mass spectrometry have been limited to very few sites and based on
a prior selection of targets. Using this workflow it was possible
to detect different phosphopeptides in an unbiased manner.
Commenting on the study, Dr Ian Pike, Chief Scientific Officer
at Proteome Sciences said:
"This study clearly demonstrates the potential of combined
tissue and fluid proteomics to discover and validate low abundant,
tissue-derived biomarkers in peripheral fluids, which in this case
resulted in the widest coverage of both tau and phosphorylated tau
in human cerebrospinal fluid.
"Many of the tau peptides showed strong regulation in the three
Alzheimer's patients relative to three controls, and these may
offer a means to earlier and more accurate diagnosis of the disease
in the future."
In addition to the most detailed profiling of CSF tau this study
has provided over 100 other regulated proteins, with several whose
genes carry mutations that increase the risk of AD, and these data
will be reported in subsequent publications.
Other contributors to the study were the University of
Gothenburg, Sweden; Sahlgrenska University Hospital, Sweden;
University College London, UK; University of Eastern Finland and
Kuopio University Hospital, Finland.
ENDS
For further information please contact:
Proteome Sciences plc
Dr. Ian Pike, Chief Operating Tel: +44 (0)1932 865065
Officer
Public Relations
IKON Associates Email: adrian@ikonassociates.com
Adrian Shaw Tel: +44 (0)1483 271291
Mobile +44(0)7979 900733
Notes for editors:
Details of the study: Comprehensive Quantitative Profiling of
Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass
Spectrometry Provides New Biomarker Candidates. Russell C.L. et al.
DOI: 10.3233/JAD-160633
Proteome Sciences performs its proprietary TMTcalibrator(TM)
biomarker discovery services for a range of clients in the
pharmaceutical industry. The technology is applicable to all
therapeutic areas where diseased tissue and diagnostic body fluids
are available.
With its HQ in Cobham, UK and laboratory facilities in London
and Frankfurt, Proteome Sciences is a leader in applied proteomics
offering high sensitivity, proprietary technologies and workflows
in cell signalling pathways (SysQuant(R), TMTcalibrator(TM)) and in
protein biomarker discovery, validation and assay development.
Proteome Sciences' research has discovered a large number of
novel protein biomarkers in key human diseases with a focus mainly
in neurological/neurodegenerative conditions and in cancer. It has
patented blood biomarkers in Alzheimer's disease, stroke, brain
damage and cancers for diagnostic and treatment applications that
are available for licenses.
www.proteomics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALBMBTMBBTTFF
(END) Dow Jones Newswires
September 22, 2016 02:01 ET (06:01 GMT)